TRK inhibitors in TRK fusion-positive cancers
Author:
Funder
Bayer AG and Loxo Oncology, Inc.
Eli Lilly and Company
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/30/Supplement_8/viii23/30959860/mdz282.pdf
Reference44 articles.
1. Implementing genome-driven oncology;Hyman;Cell,2017
2. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients;Zehir;Nat Med,2017
3. Basket trials and the evolution of clinical trial design in an era of genomic medicine;Redig;J Clin Oncol,2015
4. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N Engl J Med,2015
5. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children;Drilon;N Engl J Med,2018
Cited by 221 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of novel indazole derivatives as second-generation TRK inhibitors;European Journal of Medicinal Chemistry;2024-10
2. BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors;npj Precision Oncology;2024-09-11
3. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification;Lung Cancer;2024-09
4. Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors;Journal of Surgical Oncology;2024-07-22
5. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors;Acta Neuropathologica Communications;2024-07-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3